The biologic basis of in vivo angiogenesis imaging

Frontiers in Bioscience

Volumn 12, Issue 10, 2007, Pages 3601-3616

  Ocak, Iclal ^a   Baluk, Peter ^b   Barrett, Tristan ^a   McDonald, Donald M ^b   Choyke, Peter ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Angiogenesis; DCE MRI; Endothelial cell; Integrins; PET; Review; SPECT; Tumor neovasculature

Indexed keywords

HUMAN; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); NUCLEAR MAGNETIC RESONANCE IMAGING; REVIEW; VASCULARIZATION;

HUMANS; MAGNETIC RESONANCE IMAGING; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 34347235813     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/2337     Document Type: Article

References (94)

1. Barentsz, J. O., O. Berger-Hartog, J. A. Witjes, C. Hulsbergen-van der Kaa, G. O. Oosterhof, J. A. VanderLaak, H. Kondacki & S. H. Ruijs: Evaluation of chemotherapy in advanced urinary bladder cancer with fast dynamic contrast-enhanced MR imaging. Radiology, 207, 791-7 (1998) (Pubitemid 28279915)
2. Esserman, L., N. Hylton, T. George & N. Weidner: Contrast-Enhanced Magnetic Resonance Imaging to Assess Tumor Histopathology and Angiogenesis in Breast Carcinoma. Breast J, 5, 13-21 (1999) (Pubitemid 29108803)
3. Hulka, C. A., W. B. Edmister, B. L. Smith, L. Tan, D. C. Sgroi, T. Campbell, D. B. Kopans & R. M. Weisskoff: Dynamic echo-planar imaging of the breast: experience in diagnosing breast carcinoma and correlation with tumor angiogenesis. Radiology, 205, 837-42 (1997) (Pubitemid 27516725)
4. Kuhl, C. K., P. Mielcareck, S. Klaschik, C. Leutner, E. Wardelmann, J. Gieseke & H. H. Schild: Dynamic breast MR imaging: are signal intensity time course data useful for differential diagnosis of enhancing lesions? Radiology, 211, 101-10 (1999) (Pubitemid 29161739)
5. Baluk, P., H. Hashizume & D. M. McDonald: Cellular abnormalities of blood vessels as targets in cancer. Curr Opin Genet Dev, 15, 102-11 (2005) (Pubitemid 40127638)
6. Hashizume, H., P. Baluk, S. Morikawa, J. W. McLean, G. Thurston, S. Roberge, R. K. Jain & D. M. McDonald: Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol, 156, 1363-80 (2000) (Pubitemid 30660013)
7. Nakahara, T., S. M. Norberg, D. R. Shalinsky, D. D. Hu-Lowe & D. M. McDonald: Effect of inhibition of vascular endothelial growth factor signaling on distribution of extravasated antibodies in tumors. Cancer Res, 66, 1434-45 (2006) (Pubitemid 43259924)
8. Inai, T., M. Mancuso, H. Hashizume, F. Baffert, A. Haskell, P. Baluk, D. D. Hu-Lowe, D. R. Shalinsky, G. Thurston, G. D. Yancopoulos & D. M. McDonald: Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol, 165, 35-52 (2004) (Pubitemid 38821812)
9. Baluk, P., S. Morikawa, A. Haskell, M. Mancuso & D. M. McDonald: Abnormalities of basement membrane on blood vessels and endothelial sprouts in tumors. Am J Pathol, 163, 1801-15 (2003) (Pubitemid 37310012)
10. Armulik, A., A. Abramsson & C. Betsholtz: Endothelial/pericyte interactions. Circ Res, 97, 512-23 (2005) (Pubitemid 41361741)
11. Kalluri, R.: Basement membranes: structure, assembly and role in tumour angiogenesis. Nat Rev Cancer, 3, 422-33 (2003) (Pubitemid 37328846)
12. Neri, D. & R. Bicknell: Tumour vascular targeting. Nat Rev Cancer, 5, 436-46 (2005) (Pubitemid 40791486)
13. De Visser, K. E., A. Eichten & L. M. Coussens: Paradoxical roles of the immune system during cancer development. Nat Rev Cancer, 6, 24-37 (2006) (Pubitemid 43053650)
14. Kalluri, R. & M. Zeisberg: Fibroblasts in cancer. Nat Rev Cancer, 6, 392-401 (2006)
15. Hobbs, S. K., W. L. Monsky, F. Yuan, W. G. Roberts, L. Griffith, V. P. Torchilin & R. K. Jain: Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc Natl Acad Sci U S A, 95, 4607-12 (1998) (Pubitemid 28207960)
16. Kohn, S., J. A. Nagy, H. F. Dvorak & A. M. Dvorak: Pathways of macromolecular tracer transport across venules and small veins. Structural basis for the hyperpermeability of tumor blood vessels. Lab Invest, 67, 596-607 (1992)
17. Michel, C. C. & F. E. Curry: Microvascular permeability. Physiol Rev, 79, 703-61 (1999) (Pubitemid 29330172)
18. Padera, T. P., A. Kadambi, E. di Tomaso, C. M. Carreira, E. B. Brown, Y. Boucher, N. C. Choi, D. Mathisen, J. Wain, E. J. Mark, L. L. Munn & R. K. Jain: Lymphatic metastasis in the absence of functional intratumor lymphatics. Science, 296, 1883-6 (2002) (Pubitemid 34596277)
19. Ruoslahti, E.: Specialization of tumour vasculature. Nat Rev Cancer, 2, 83-90 (2002) (Pubitemid 37328795)
20. Jain, R. K.: Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science, 307, 58-62 (2005) (Pubitemid 40093472)
21. McDonald, D. M. & P. L. Choyke: Imaging of angiogenesis: from microscope to clinic. Nat Med, 9, 713-25 (2003) (Pubitemid 36749220)
22. Willett, C. G., Y. Boucher, E. di Tomaso, D. G. Duda, L. L. Munn, R. T. Tong, D. C. Chung, D. V. Sahani, S. P. Kalva, S. V. Kozin, M. Mino, K. S. Cohen, D. T. Scadden, A. C. Hartford, A. J. Fischman, J. W. Clark, D. P. Ryan, A. X. Zhu, L. S. Blaszkowsky, H. X. Chen, P. C. Shellito, G. Y. Lauwers & R. K. Jain: Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med, 10, 145-7 (2004) (Pubitemid 38524883)
23. Padhani, A. R. & M. O. Leach: Antivascular cancer treatments: functional assessments by dynamic contrastenhanced magnetic resonance imaging. Abdom Imaging, 30, 324-41 (2005) (Pubitemid 40898066)
24. Tofts, P. S., G. Brix, D. L. Buckley, J. L. Evelhoch, E. Henderson, M. V. Knopp, H. B. Larsson, T. Y. Lee, N. A. Mayr, G. J. Parker, R. E. Port, J. Taylor & R. M. Weisskoff: Estimating kinetic parameters from dynamic contrast-enhanced T (1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging, 10, 223-32 (1999) (Pubitemid 29463104)
25. Choyke, P. L., A. J. Dwyer & M. V. Knopp: Functional tumor imaging with dynamic contrast-enhanced magnetic resonance imaging. J Magn Reson Imaging, 17, 509-20 (2003) (Pubitemid 36528666)
26. Brix, G., W. Semmler, R. Port, L. R. Schad, G. Layer & W. J. Lorenz: Pharmacokinetic parameters in CNS Gd-DTPA enhanced MR imaging. J Comput Assist Tomogr, 15, 621-8 (1991)
27. Furman-Haran, E., R. Margalit, D. Grobgeld & H. Degani: Dynamic contrast-enhanced magnetic resonance imaging reveals stress-induced angiogenesis in MCF7 human breast tumors. Proc Natl Acad Sci U S A, 93, 6247-51 (1996)
28. Knopp, M. V., F. L. Giesel, H. Marcos, H. von Tengg-Kobligk & P. Choyke: Dynamic contrast-enhanced magnetic resonance imaging in oncology. Top Magn Reson Imaging, 12, 301-8 (2001) (Pubitemid 33031399)
29. Marzola, P., A. Degrassi, L. Calderan, P. Farace, C. Crescimanno, E. Nicolato, A. Giusti, E. Pesenti, A. Terron, A. Sbarbati, T. Abrams, L. Murray & F. Osculati: In vivo assessment of antiangiogenic activity of SU6668 in an experimental colon carcinoma model. Clin Cancer Res, 10, 739-50 (2004) (Pubitemid 38174012)
30. Lee, L., S. Sharma, B. Morgan, P. Allegrini, C. Schnell, J. Brueggen, R. Cozens, M. Horsfield, C. Guenther, W. P. Steward, J. Drevs, D. Lebwohl, J. Wood & P. M. McSheehy: Biomarkers for assessment of pharmacologic activity for a vascular endothelial growth factor (VEGF) receptor inhibitor, PTK787/ZK 222584 (PTK/ZK): translation of biological activity in a mouse melanoma metastasis model to phase I studies in patients with advanced colorectal cancer with liver metastases. Cancer Chemother Pharmacol, 57, 761-71 (2006)
31. De Lussanet, Q. G., R. G. Beets-Tan, W. H. Backes, D. W. van der Schaft, J. M. van Engelshoven, K. H. Mayo & A. W. Griffioen: Dynamic contrast-enhanced magnetic resonance imaging at 1.5 Tesla with gadopentetate dimeglumine to assess the angiostatic effects of anginex in mice. Eur J Cancer, 40, 1262-8 (2004) (Pubitemid 38526347)
32. Morgan, B., A. L. Thomas, J. Drevs, J. Hennig, M. Buchert, A. Jivan, M. A. Horsfield, K. Mross, H. A. Ball, L. Lee, W. Mietlowski, S. Fuxuis, C. Unger, K. O'Byrne, A. Henry, G. R. Cherryman, D. Laurent, M. Dugan, D. Marme & W. P. Steward: Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J Clin Oncol, 21, 3955-64 (2003) (Pubitemid 46606209)
33. Liu, G., H. S. Rugo, G. Wilding, T. M. McShane, J. L. Evelhoch, C. Ng, E. Jackson, F. Kelcz, B. M. Yeh, F. T. Lee, Jr., C. Charnsangavej, J. W. Park, E. A. Ashton, H. M. Steinfeldt, Y. K. Pithavala, S. D. Reich & R. S. Herbst: Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study. J Clin Oncol, 23, 5464-73 (2005)
34. Wedam, S. B., J. A. Low, S. X. Yang, C. K. Chow, P. Choyke, D. Danforth, S. M. Hewitt, A. Berman, S. M. Steinberg, D. J. Liewehr, J. Plehn, A. Doshi, D. Thomasson, N. McCarthy, H. Koeppen, M. Sherman, J. Zujewski, K. Camphausen, H. Chen & S. M. Swain: Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol, 24, 769-77 (2006) (Pubitemid 46622044)
35. Xiong, H. Q., R. Herbst, S. C. Faria, C. Scholz, D. Davis, E. F. Jackson, T. Madden, D. McConkey, M. Hicks, K. Hess, C. A. Charnsangavej & J. L. Abbruzzese: A phase I surrogate endpoint study of SU6668 in patients with solid tumors. Invest New Drugs, 22, 459-66 (2004) (Pubitemid 39619822)
36. Huang, X., M. K. Wong, H. Yi, S. Watkins, A. D. Laird, S. F. Wolf & E. Gorelik: Combined therapy of local and metastatic 4T1 breast tumor in mice using SU6668, an inhibitor of angiogenic receptor tyrosine kinases, and the immunostimulator B7.2-IgG fusion protein. Cancer Res, 62, 5727-35 (2002) (Pubitemid 35204728)
37. Ning, S., D. Laird, J. M. Cherrington & S. J. Knox: The antiangiogenic agents SU5416 and SU6668 increase the antitumor effects of fractionated irradiation. Radiat Res, 157, 45-51 (2002) (Pubitemid 34073387)
38. Medved, M., G. Karczmar, C. Yang, J. Dignam, T. F. Gajewski, H. Kindler, E. Vokes, P. MacEneany, M. T. Mitchell & W. M. Stadler: Semiquantitative analysis of dynamic contrast enhanced MRI in cancer patients: Variability and changes in tumor tissue over time. J Magn Reson Imaging, 20, 122-8 (2004) (Pubitemid 38857525)
39. Preda, A., M. van Vliet, G. P. Krestin, R. C. Brasch & C. F. van Dijke: Magnetic resonance macromolecular agents for monitoring tumor microvessels and angiogenesis inhibition. Invest Radiol, 41, 325-31 (2006) (Pubitemid 44406194)
40. Kowanetz, M. & N. Ferrara: Vascular endothelial growth factor signaling pathways: therapeutic perspective. Clin Cancer Res, 12, 5018-22 (2006) (Pubitemid 44453326)
41. Olsson, A. K., A. Dimberg, J. Kreuger & L. Claesson-Welsh: VEGF receptor signalling - in control of vascular function. Nat Rev Mol Cell Biol, 7, 359-71 (2006)
42. Kamba, T., B. Y. Tam, H. Hashizume, A. Haskell, B. Sennino, M. R. Mancuso, S. M. Norberg, S. M. O'Brien, R. B. Davis, L. C. Gowen, K. D. Anderson, G. Thurston, S. Joho, M. L. Springer, C. J. Kuo & D. M. McDonald: VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am J Physiol Heart Circ Physiol, 290, H560-76 (2006)
43. Nanda, A. & B. St Croix: Tumor endothelial markers: new targets for cancer therapy. Curr Opin Oncol, 16, 44-9 (2004) (Pubitemid 38703471)
44. St Croix, B., C. Rago, V. Velculescu, G. Traverso, K. E. Romans, E. Montgomery, A. Lal, G. J. Riggins, C. Lengauer, B. Vogelstein & K. W. Kinzler: Genes expressed in human tumor endothelium. Science, 289, 1197-202 (2000) (Pubitemid 30650733)
45. Arap, W., M. G. Kolonin, M. Trepel, J. Lahdenranta, M. Cardo-Vila, R. J. Giordano, P. J. Mintz, P. U. Ardelt, V. J. Yao, C. I. Vidal, L. Chen, A. Flamm, H. Valtanen, L. M. Weavind, M. E. Hicks, R. E. Pollock, G. H. Botz, C. D. Bucana, E. Koivunen, D. Cahill, P. Troncoso, K. A. Baggerly, R. D. Pentz, K. A. Do, C. J. Logothetis & R. Pasqualini: Steps toward mapping the human vasculature by phage display. Nat Med, 8, 121-7 (2002) (Pubitemid 34155122)
46. Hajitou, A., R. Pasqualini & W. Arap: Vascular targeting: recent advances and therapeutic perspectives. Trends Cardiovasc Med, 16, 80-8 (2006)
47. Pilch, J., D. M. Brown, M. Komatsu, T. A. Jarvinen, M. Yang, D. Peters, R. M. Hoffman & E. Ruoslahti: Peptides selected for binding to clotted plasma accumulate in tumor stroma and wounds. Proc Natl Acad Sci U S A, 103, 2800-4 (2006)
48. Ruoslahti, E.: Vascular zip codes in angiogenesis and metastasis. Biochem Soc Trans, 32, 397-402 (2004) (Pubitemid 38813523)
49. Brooks, P. C., S. Stromblad, R. Klemke, D. Visscher, F. H. Sarkar & D. A. Cheresh: Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest, 96, 1815-22 (1995)
50. Eliceiri, B. P. & D. A. Cheresh: Role of alpha v integrins during angiogenesis. Cancer J, 6 Suppl 3, S245-9 (2000)
51. Hood, J. D. & D. A. Cheresh: Role of integrins in cell invasion and migration. Nat Rev Cancer, 2, 91-100 (2002) (Pubitemid 37328796)
52. Kim, S., K. Bell, S. A. Mousa & J. A. Varner: Regulation of angiogenesis in vivo by ligation of integrin alpha5beta1 with the central cell-binding domain of fibronectin. Am J Pathol, 156, 1345-62 (2000) (Pubitemid 30660012)
53. Parsons-Wingerter, P., I. M. Kasman, S. Norberg, A. Magnussen, S. Zanivan, A. Rissone, P. Baluk, C. J. Favre, U. Jeffry, R. Murray & D. M. McDonald: Uniform overexpression and rapid accessibility of alpha5beta1 integrin on blood vessels in tumors. Am J Pathol, 167, 193-211 (2005) (Pubitemid 40884781)
54. Hynes, R. O.: A reevaluation of integrins as regulators of angiogenesis. Nat Med, 8, 918-21 (2002) (Pubitemid 35033683)
55. Taverna, D., H. Moher, D. Crowley, L. Borsig, A. Varki & R. O. Hynes: Increased primary tumor growth in mice null for beta3-or beta3/beta5-integrins or selectins. Proc Natl Acad Sci U S A, 101, 763-8 (2004) (Pubitemid 38121032)
56. Jin, H. & J. Varner: Integrins: roles in cancer development and as treatment targets. Br J Cancer, 90, 561-5 (2004) (Pubitemid 38297190)
57. Magnussen, A., I. M. Kasman, S. Norberg, P. Baluk, R. Murray & D. M. McDonald: Rapid access of antibodies to alpha5beta1 integrin overexpressed on the luminal surface of tumor blood vessels. Cancer Res, 65, 2712-21 (2005) (Pubitemid 40490072)
58. Meyer, A., J. Auernheimer, A. Modlinger & H. Kessler: Targeting RGD recognizing integrins: drug development, biomaterial research, tumor imaging and targeting. Curr Pharm Des, 12, 2723-47 (2006) (Pubitemid 44184633)
59. Yao, V. J., M. G. Ozawa, A. S. Varner, I. M. Kasman, Y. H. Chanthery, R. Pasqualini, W. Arap & D. M. McDonald: Antiangiogenic therapy decreases integrin expression in normalized tumor blood vessels. Cancer Res, 66, 2639-49 (2006)
60. Miller, J. C., H. H. Pien, D. Sahani, A. G. Sorensen & J. H. Thrall: Imaging angiogenesis: applications and potential for drug development. J Natl Cancer Inst, 97, 172-87 (2005) (Pubitemid 40277367)
61. Ruoslahti, E. & M. D. Pierschbacher: Arg-Gly-Asp: a versatile cell recognition signal. Cell, 44, 517-8 (1986)
62. Xiong, Z., Z. Cheng, X. Zhang, M. Patel, J. C. Wu, S. S. Gambhir & X. Chen: Imaging Chemically Modified Adenovirus for Targeting Tumors Expressing Integrin {alpha}v{beta}3 in Living Mice with Mutant Herpes Simplex Virus Type 1 Thymidine Kinase PET Reporter Gene. J Nucl Med, 47, 130-139 (2006) (Pubitemid 46768522)
63. Mousa, S. A.: Alpha v integrin affinity/specificity and antiangiogenesis effect of a novel tetraaza cyclic peptide derivative, SU015, in various species. J Cardiovasc Pharmacol, 45, 462-7 (2005) (Pubitemid 40627966)
64. Gould, R. J., M. A. Polokoff, P. A. Friedman, T. F. Huang, J. C. Holt, J. J. Cook & S. Niewiarowski: Disintegrins: a family of integrin inhibitory proteins from viper venoms. Proc Soc Exp Biol Med, 195, 168-71 (1990) (Pubitemid 20373198)
65. Pfaff, M., M. A. McLane, L. Beviglia, S. Niewiarowski & R. Timpl: Comparison of disintegrins with limited variation in the RGD loop in their binding to purified integrins alpha IIb beta 3, alpha V beta 3 and alpha 5 beta 1 and in cell adhesion inhibition. Cell Adhes Commun, 2, 491-501 (1994)
66. Charo, I. F., L. Nannizzi, J. W. Smith & D. A. Cheresh: The vitronectin receptor alpha v beta 3 binds fibronectin and acts in concert with alpha 5 beta 1 in promoting cellular attachment and spreading on fibronectin. J Cell Biol, 111, 2795-800 (1990) (Pubitemid 120014560)
67. Sipkins, D. A., D. A. Cheresh, M. R. Kazemi, L. M. Nevin, M. D. Bednarski & K. C. Li: Detection of tumor angiogenesis in vivo by alphaVbeta3-targeted magnetic resonance imaging. Nat Med, 4, 623-6 (1998) (Pubitemid 28237365)
68. Houston, J. P., S. Ke, W. Wang, C. Li & E. M. Sevick-Muraca: Quality analysis of in vivo near-infrared fluorescence and conventional gamma images acquired using a dual-labeled tumor-targeting probe. J Biomed Opt, 10, 054010 (2005)
69. Wu, Y., X. Zhang, Z. Xiong, Z. Cheng, D. R. Fisher, S. Liu, S. S. Gambhir & X. Chen: microPET imaging of glioma integrin {alpha}v{beta}3 expression using (64) Culabeled tetrameric RGD peptide. J Nucl Med, 46, 1707-18 (2005) (Pubitemid 46211595)
70. Zhang, X., Z. Xiong, Y. Wu, W. Cai, J. R. Tseng, S. S. Gambhir & X. Chen: Quantitative PET Imaging of Tumor Integrin {alpha}v{beta}3 Expression with 18F-FRGD2. J Nucl Med, 47, 113-21 (2006) (Pubitemid 46768520)
71. Wilson, C. B., A. A. Lammertsma, C. G. McKenzie, K. Sikora & T. Jones: Measurements of blood flow and exchanging water space in breast tumors using positron emission tomography: a rapid and noninvasive dynamic method. Cancer Res, 52, 1592-7 (1992)
72. Collingridge, D. R., V. A. Carroll, M. Glaser, E. O. Aboagye, S. Osman, O. C. Hutchinson, H. Barthel, S. K. Luthra, F. Brady, R. Bicknell, P. Price & A. L. Harris: The development of [(124) I]iodinated-VG76e: a novel tracer for imaging vascular endothelial growth factor in vivo using positron emission tomography. Cancer Res, 62, 5912-9 (2002) (Pubitemid 35204754)
73. Winter, P. M., S. D. Caruthers, A. Kassner, T. D. Harris, L. K. Chinen, J. S. Allen, E. K. Lacy, H. Zhang, J. D. Robertson, S. A. Wickline & G. M. Lanza: Molecular imaging of angiogenesis in nascent Vx-2 rabbit tumors using a novel alpha (nu) beta3-targeted nanoparticle and 1.5 tesla magnetic resonance imaging. Cancer Res, 63, 5838-43 (2003) (Pubitemid 37187482)
74. Mulder, W. J., G. J. Strijkers, J. W. Habets, E. J. Bleeker, D. W. van der Schaft, G. Storm, G. A. Koning, A. W. Griffioen & K. Nicolay: MR molecular imaging and fluorescence microscopy for identification of activated tumor endothelium using a bimodal lipidic nanoparticle. Faseb J, 19, 2008-10 (2005) (Pubitemid 41759747)
75. Ellegala, D. B., H. Leong-Poi, J. E. Carpenter, A. L. Klibanov, S. Kaul, M. E. Shaffrey, J. Sklenar & J. R. Lindner: Imaging tumor angiogenesis with contrast ultrasound and microbubbles targeted to alpha (v) beta3. Circulation, 108, 336-41 (2003) (Pubitemid 36899026)
76. Zhao, S., M. Borden, S. H. Bloch, D. Kruse, K. W. Ferrara & P. A. Dayton: Radiation-force assisted targeting facilitates ultrasonic molecular imaging. Mol Imaging, 3, 135-48 (2004)
77. Cheng, Z., Y. Wu, Z. Xiong, S. S. Gambhir & X. Chen: Near-infrared fluorescent RGD peptides for optical imaging of integrin alphavbeta3 expression in living mice. Bioconjug Chem, 16, 1433-41 (2005) (Pubitemid 41681509)
78. Aina, O. H., J. Marik, R. Gandour-Edwards & K. S. Lam: Near-infrared optical imaging of ovarian cancer xenografts with novel alpha 3-integrin binding peptide "OA02". Mol Imaging, 4, 439-47 (2005) (Pubitemid 43143784)
79. Baluk, P., C. G. Lee, H. Link, E. Ator, A. Haskell, J. A. Elias, D. M. McDonald: Regulated angiogenesis and vascular regression in mice overexpressing vascular endothelial growth factor in airways. Am J Pathol, 165, 1071-85 (2004) (Pubitemid 39297715)
80. Chen, X., R. Park, A. H. Shahinian, M. Tohme, V. Khankaldyyan, M. H. Bozorgzadeh, J. R. Bading, R. Moats, W. E. Laug & P. S. Conti: 18F-labeled RGD peptide: initial evaluation for imaging brain tumor angiogenesis. Nucl Med Biol, 31, 179-89 (2004) (Pubitemid 38315112)
81. Mross, K., J. Drevs, M. Muller, M. Medinger, D. Marme, J. Hennig, B. Morgan, D. Lebwohl, E. Masson, Y. Y. Ho, C. Gunther, D. Laurent & C. Unger: Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumours. Eur J Cancer, 41, 1291-9 (2005) (Pubitemid 40813005)
82. Thomas, A. L., B. Morgan, M. A. Horsfield, A. Higginson, A. Kay, L. Lee, E. Masson, M. Puccio-Pick, D. Laurent & W. P. Steward: Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered twice daily in patients with advanced cancer. J Clin Oncol, 23, 4162-71 (2005) (Pubitemid 46211322)
83. Galbraith, S. M., R. J. Maxwell, M. A. Lodge, G. M. Tozer, J. Wilson, N. J. Taylor, J. J. Stirling, L. Sena, A. R. Padhani & G. J. Rustin: Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging. J Clin Oncol, 21, 2831-42 (2003) (Pubitemid 46621830)
84. Burrows, F. J., E. J. Derbyshire, P. L. Tazzari, P. Amlot, A. F. Gazdar, S. W. King, M. Letarte, E. S. Vitetta & P. E. Thorpe: Up-regulation of endoglin on vascular endothelial cells in human solid tumors: implications for diagnosis and therapy. Clin Cancer Res, 1, 1623-34 (1995) (Pubitemid 26030991)
85. Takahashi, N., A. Haba, F. Matsuno & B. K. Seon: Antiangiogenic therapy of established tumors in human skin/severe combined immunodeficiency mouse chimeras by anti-endoglin (CD105) monoclonal antibodies, and synergy between anti-endoglin antibody and cyclophosphamide. Cancer Res, 61, 7846-54 (2001) (Pubitemid 33049374)
86. Jin, H., J. Su, B. Garmy-Susini, J. Kleeman & J. Varner: Integrin alpha4beta1 promotes monocyte trafficking and angiogenesis in tumors. Cancer Res, 66, 2146-52 (2006)
87. Huang, X., M. Bennett & P. E. Thorpe: A monoclonal antibody that binds anionic phospholipids on tumor blood vessels enhances the antitumor effect of docetaxel on human breast tumors in mice. Cancer Res, 65, 4408-16 (2005) (Pubitemid 40775680)
88. Joyce, J. A., P. Laakkonen, M. Bernasconi, G. Bergers, E. Ruoslahti & D. Hanahan: Stage-specific vascular markers revealed by phage display in a mouse model of pancreatic islet tumorigenesis. Cancer Cell, 4, 393-403 (2003) (Pubitemid 37491100)
89. Madden, S. L., B. P. Cook, M. Nacht, W. D. Weber, M. R. Callahan, Y. Jiang, M. R. Dufault, X. Zhang, W. Zhang, J. Walter-Yohrling, C. Rouleau, V. R. Akmaev, C. J. Wang, X. Cao, T. B. St Martin, B. L. Roberts, B. A. Teicher, K. W. Klinger, R. V. Stan, B. Lucey, E. B. Carson-Walter, J. Laterra & K. A. Walter: Vascular gene expression in nonneoplastic and malignant brain. Am J Pathol, 165, 601-8 (2004) (Pubitemid 38971389)
90. Ridgway, J., G. Zhang, Y. Wu, S. Stawicki, W. C. Liang, Y. Chanthery, J. Kowalski, R. J. Watts, C. Callahan, I. Kasman, M. Singh, M. Chien, C. Tan, J. A. Hongo, F. de Sauvage, G. Plowman & M. Yan: Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis. Nature, 444, 1083-7 (2006) (Pubitemid 46018529)
91. Noguera-Troise, I., C. Daly, N. J. Papadopoulos, S. Coetzee, P. Boland, N. W. Gale, H. C. Lin, G. D. Yancopoulos & G. Thurston: Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. Nature, 444, 1032-7 (2006) (Pubitemid 46018516)
92. Chang, S. S., D. S. O'Keefe, D. J. Bacich, V. E. Reuter, W. D. Heston & P. B. Gaudin: Prostate-specific membrane antigen is produced in tumor-associated neovasculature. Clin Cancer Res, 5, 2674-81 (1999) (Pubitemid 29493938)
93. Beaty, R. M., J. B. Edwards, K. Boon, I. M. Siu, J. E. Conway & G. J. Riggins: PLXDC1 (TEM7) is identified in a genome-wide expression screen of glioblastoma endothelium. J Neurooncol (2006)
94. Brekken, R. A., X. Huang, S. W. King & P. E. Thorpe: Vascular endothelial growth factor as a marker of tumor endothelium. Cancer Res, 58, 1952-9 (1998) (Pubitemid 28217472)